Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 677 of 5804
-
New PKU drug could loosen strict diet restrictions
Disease control OngoingThe main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New device aims to beat standard care for dangerous lung clots
Disease control CompletedA prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thr…
Phase: NA • Sponsor: Inari Medical • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New Diet-Drug cocktail targets deadliest brain tumor
Disease control TerminatedThis study is for patients with newly diagnosed glioblastoma, as well as patients who have recurring glioblastoma. Subjects will be given daily paxalisib and metformin while also maintaining a ketogenic diet. The purpose of this study is to assess the safety of Paxalisib while m…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Liver fluke drug proves safe in largest study yet
⭐️ CURE ⭐️ CompletedThis is a multicenter, open label, non-comparative, single arm multi-country study in approximately 300 adult and pediatric subjects (≥ 6 years of age) with fascioliasis. The study population consists of male and female adult and pediatric patients (≥ 6 years of age). The study w…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:37 UTC
-
Promising drug combo targets Tough-to-Treat lymphoma
Disease control Recruiting nowThe purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
Phase: PHASE2 • Sponsor: Juan P. Alderuccio, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lymphoma patients who Can't take chemo
Disease control OngoingAim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned…
Phase: PHASE2 • Sponsor: International Extranodal Lymphoma Study Group (IELSG) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for kids with Crohn's: drug aims to keep disease in check
Disease control Recruiting nowVedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission a…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Pill combo could replace harsh chemo for High-Risk leukemia
Disease control OngoingThis phase Ib/II trial studies the effects of ASTX727 (decitabine and cedazuridine) in combination with venetoclax in treating patients with higher-risk acute myeloid leukemia patients who do not have a change in the gene called fms-like tyrosine kinase 3 (FLT3). Decitabine is in…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo tackles tough lymphoma
Disease control CompletedAim of this study will evaluate the Efficacy and Safety of XPO-1 inhibitors in combination with CAR-T cells in relapsed refractory B-cell non-Hodgkin's lymphoma
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat myeloma: targeted combo enters Late-Stage trial
Disease control OngoingThis study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New balloon could save legs from amputation in PAD patients
Disease control OngoingThis study is a prospective, interventional, multicenter 1:1 randomized trial. The trial evaluates the safety and efficacy of the Magic Touch PTA sirolimus drug-coated balloon in comparison to the treatment with POBA (control device) in patients with advanced infrapopliteal arte…
Phase: NA • Sponsor: Jena University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo therapy shows promise for untreatable liver cancer
Disease control Recruiting nowThis study adopted a bidirectional cohort study design. On the one hand, the previous clinical data, treatment exposure and clinical endpoint events of the enrolled patients were retrospectively collected. On the other hand, prospective regular follow-up was conducted from the da…
Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could a repurposed drug boost immune attack on childhood brain tumors?
Disease control Recruiting nowRecent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutini…
Phase: PHASE1 • Sponsor: Theodore S. Johnson • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New combo shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingSintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity. This study is a phase III clinical study of a three-week regimen of sintilima…
Phase: PHASE3 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a better diet during malnutrition recovery rewire a Child's brain?
Disease control CompletedThe study explores the impact of malnutrition at enrollment on executive function (EF) and emotional regulation (ER) in malnourished 1-year-old children and whether specially designed brain directed therapeutic feeds improve EF/ER outcomes at three years of age. The study will de…
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New shot could cut COPD attacks in former smokers
Disease control CompletedThe purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Parti…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can an arthritis drug make melanoma immunotherapy safer?
Disease control OngoingThe purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New pill combo could shrink lung tumors before surgery
Disease control OngoingIn the randomized, multicenter Phase II clinical trial, we aim to evaluate the efficacy and safety of Lazertinib monotherapy or the combination of Lazertinib and cytotoxic chemotherapy as neoadjuvant therapy in patients with resectable, treatment-naive EGFR-mutant (exon 19 deleti…
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New trial tests deep sleep vs. strong meds for hidden seizures
Disease control Recruiting nowThis open-label, randomized multicenter trial aims at clarifying the standard of care of patients with non-convulsive status epilepticus not responding to treatment with benzodiazepines and at least one high-dose intra venous anti-seizure medication.
Phase: PHASE3 • Sponsor: University of Southern Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a single gene therapy injection slow Alzheimer's?
Disease control OngoingThis is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairme…
Phase: PHASE1 • Sponsor: Mark Tuszynski • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC